Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tacrolimus
Drug ID BADD_D02105
Description Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription.
Indications and Usage For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Marketing Status Prescription; Discontinued
ATC Code D11AH01; L04AD02
DrugBank ID DB00864
KEGG ID D00107
MeSH ID D016559
PubChem ID 445643
TTD Drug ID D06OMK
NDC Product Code 16729-041; 0781-2104; 70748-219; 52972-0040; 0168-0416; 70748-220; 70377-014; 16729-043; 43353-317; 68254-0002; 49629-022; 0469-1330; 68084-450; 49629-020; 70518-3022; 68462-534; 69452-153; 55111-527; 55111-525; 47848-018; 16714-098; 65897-1010; 38779-2698; 62250-665; 68084-449; 52928-006; 0904-6623; 50222-211; 49629-021; 68992-3075; 45802-700; 43817-423; 63629-8726; 70748-221; 68254-5005; 68462-685; 0781-2103; 69452-154; 50090-2245; 69452-155; 0469-3016; 54288-135; 0904-7097; 0904-6425; 68254-0020; 0378-2047; 73377-010; 60429-378; 50090-5596; 65050-0321; 50222-203; 0781-2102; 16729-042; 68084-451; 0168-0417; 0378-2045; 63629-8725; 0904-6624; 55154-4080; 55486-1576; 45802-390; 51927-0092; 0469-0607; 68308-703; 68254-5004; 60429-377; 68462-686; 64380-721; 0469-0617; 0378-2046; 62991-3072; 67877-278; 43817-421; 64380-720; 51079-028; 64380-722; 70518-3216; 51079-818; 68254-2502; 51187-0006; 55111-526; 70377-015; 70518-2996; 67877-279; 0469-1230; 68254-5006; 65727-009; 0469-0657; 70377-016; 70518-2593; 16729-422; 51079-817; 60429-379; 16729-421; 68992-3040; 16714-100; 70518-2124; 63629-8723; 72572-761; 67877-280; 55500-0010; 50090-5581; 68992-3010; 51552-1403; 72572-760; 16714-099; 68462-687; 82160-124; 70518-3388; 43817-422; 52076-6222
Synonyms Tacrolimus | Prograf | Prograft | FR-900506 | FR 900506 | FR900506 | Anhydrous Tacrolimus | Tacrolimus, Anhydrous | Tacrolimus Anhydrous | Anhydrous, Tacrolimus | FK-506 | FK 506 | FK506
Chemical Information
Molecular Formula C44H69NO12
CAS Registry Number 104987-11-3
SMILES CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC 4CCC(C(C4)OC)O)C)O)C)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Nephropathy toxicCalcineurin subunit B type 1P63098Not Available8591053; 7694398; 7592869; 7533090
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coagulopathy01.01.02.0010.003548%Not Available
Coccidioidomycosis22.07.08.004; 11.03.09.0010.004258%Not Available
Colitis07.08.01.0010.004258%
Colitis ulcerative10.02.01.004; 07.08.01.0050.012065%Not Available
Colon cancer16.13.01.001; 07.21.01.001--Not Available
Coma17.02.09.001--Not Available
Concussion12.01.10.005; 17.11.01.0040.002129%Not Available
Condition aggravated08.01.03.004--Not Available
Confusional state19.13.01.001; 17.02.03.0050.034065%
Congenital cystic kidney disease03.06.01.003; 20.01.04.006; 16.27.01.0020.001419%Not Available
Conjunctival oedema06.04.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Conjunctivitis allergic10.01.04.002; 06.04.01.0030.001419%Not Available
Constipation07.02.02.001--
Coombs positive haemolytic anaemia10.04.01.001; 01.06.01.0010.001419%Not Available
Coordination abnormal17.02.02.004--Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.0060.001419%Not Available
Cough22.02.03.001--
Crepitations08.01.03.0060.002129%Not Available
Crohn's disease10.02.01.005; 07.08.01.0150.003548%Not Available
Cryptococcosis11.03.04.0010.004968%Not Available
Cryptosporidiosis infection11.06.02.001; 07.19.03.0020.001419%Not Available
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.001--Not Available
Cyst08.03.05.001; 16.02.02.002--Not Available
Cystitis20.03.02.002; 11.01.14.001--
Cystitis haemorrhagic20.03.02.0030.003548%Not Available
Cytomegalovirus infection11.05.01.0020.048969%
Deafness04.02.01.0010.004968%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.0020.002129%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 46 Pages